Ocugen, Inc. OCGN

Rank #2452 · Nasdaq · $0.2B market cap

⚠ Going-concern flag — the auditor (PricewaterhouseCoopers LLP) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.

Score

16.9

P/E

-4.4

P/B

5.86

ROE

-133.3%

Op. Margin

-1350.4%

Debt Ratio

130%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆

Weak

P/E -4.4x, P/B 5.86x. Ranks in the top 80% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -133.3%. Ranks in the top 96% of the universe.

Safety ★★★☆☆

Average

Debt ratio 130%. Ranks in the top 48% of the universe.

Growth ★☆☆☆☆

Poor

Revenue decline of 32.8% year over year. Ranks in the top 95% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2015	–	$-0.0B	$-0.0B	$-0.1B	–	-15
2016	–	$-0.0B	$-0.0B	$0.1B	–	16
2017	–	$-0.0B	$-0.0B	$0.0B	–	80
2018	$0.0B	$-0.0B	$-0.0B	$0.0B	–	164
2019	–	$-0.0B	$-0.0B	$0.0B	–	342
2020	$0.0B	$-0.0B	$-0.0B	$-0.0B	–	-46
2021	$0.0B	$-0.0B	$-0.0B	$-0.0B	–	-46
2022	–	$-0.1B	$-0.1B	$0.0B	–	46
2023	$0.0B	$-0.1B	$-0.1B	$0.1B	-3580.0	18
2024	$0.0B	$-0.1B	$-0.1B	$0.1B	-1085.7	32
2025	$0.0B	$-0.1B	$-0.1B	$0.0B	-1350.4	130

← See the full screener